Introduction
Recent advances in pulmonary arterial hypertension (PAH)-specific drugs have dramatically changed the therapeutic strategy for PAH. A strategy that includes 'treatment' with PAH-specific drugs initially and then 'repair' by closure of the cardiac defect (i.e. 'treat and repair') was devised, and has been attempted, in patients with PAH associated with a cardiac defect. 
Case presentation
We present three cases of severe PAH associated with a ventricular septal defect (VSD) in adult patients who were initially treated with PAH-specific drugs followed by VSD closure. Two of the patients were treated with a combination of an endothelin receptor antagonist (ERA), phosphodiesterase type 5 inhibitor, and intravenous prostacyclin before VSD closure. The third patient was treated with an ERA and pulmonary artery banding before VSD closure. After 12 months of anti-PAH treatment, the pulmonary vascular resistance index and the ratio of the pulmonary vascular index to the systemic vascular resistance index decreased to levels that allowed VSD closure. At the mid-and long-term follow-up measurements after surgical closure of the VSD, the mean pulmonary artery pressure had markedly decreased. 
Introduction
Pulmonary arterial hypertension (PAH) is characterized by vasoconstriction and remodelling of pulmonary arteries, leading to elevated pulmonary artery pressure and right heart failure. Congenital shunt disease is one of the causes of PAH. 1 High flow by systemic-topulmonary (S/P) shunting through a cardiac defect increases shear stress of the pulmonary artery wall and can ultimately remodel pulmonary arteries. 2 In an animal study, the disappearance of shunt flow caused pulmonary arterial vasculopathy to regress after flow correction. 3, 4 Regression of shunt flow by cardiac defect closure can stop progression of PAH and might reverse remodelling of pulmonary arteries.
In the 2015 European Society of Cardiology guidelines, PAH associated with congenital heart diseases (CHD) is divided into four clinical groups: (i) Eisenmenger syndrome; (ii) PAH associated with a prevalent S/P shunt; (iii) PAH with small/coincidental defects; and (iv) PAH after defect correction. 1 Defect closure is a contraindication in those with Eisenmenger syndrome or PAH with small/coincidental defects. The feasibility of defect closure based on pulmonary vascular resistance (PVR) was studied in patients with PAH associated with a prevalent S/P shunt. Defect closure is possible in patients with PAH associated with an S/P shunt who have low PVR. 5 Recently, a 'treat-and-repair' strategy has been considered in patients who have S/P shunting but high PVR initially. 6 A cardiac defect can be closed in patients whose PVR decreases after treatment with PAH-specific drugs. It remains unknown; however, which patients would benefit from a treat-andrepair strategy, what sort of anti-PAH treatment is effective, and when to perform surgical closure. We report three adult patients with PAH associated with a ventricular septal defect (VSD) in whom a treat-and-repair strategy was used.
Patient 1
A 49-year-old woman was diagnosed with VSD at birth and underwent pulmonary artery banding during infancy. She was recently diagnosed with severe PAH and was referred to our hospital for treatment. The patient had dyspnoea. Her heart rate was 111 b.p.m., blood pressure 126/94 mmHg, and SpO 2 92% with oxygen administration at 2 L/min. Cardiovascular examination revealed increased intensity of P2 and pansystolic murmur at the third right intercostal space on auscultation and parasternal heave. The lung field were clear. 
Patient 2
A 20-year-old man had been diagnosed with VSD and PAH at birth in another hospital. Treatment with sildenafil 60 mg and ambrisentan 10 mg was started at age 5 years. The patient was referred to our hospital at age 20 years. The patient had slight dyspnoea. His heart rate was 58 b.p.m., blood pressure 97/52 mmHg, and SpO 2 94% in room air. Cardiovascular examination revealed increased intensity of P2 and pansystolic murmur at the third right intercostal space on auscultation and parasternal heave. The lung field were clear. The remainder of the physical examination was unremarkable. Transthoracic echocardiography showed perimembranous-type VSD (18 Â 18 mm) with left-to-right shunt, dilated right ventricle, and estimated right ventricular systolic pressure of 91 mmHg ( 
Timeline Patient 3
A 49-year-old woman was diagnosed with VSD and PAH at 2 years of age in another hospital. Left pulmonary artery banding was performed at age 4 years. Treatment with ambrisentan and warfarin was started at age 18 years. At age 49 years, the patient was referred to our hospital for possible VSD closure. 
Discussion
During the natural history of PAH associated with VSD in adult patients, PAH and right heart failure develop, ultimately leading to a change from left-to-right shunting to right-to-left shunting (i.e. Eisenmenger syndrome). This condition then leads to severe hypoxia, cyanosis, and death. Recent advances in PAH-specific drugs have dramatically changed the treatment for PAH to a treatment-and-repair strategy. 7 Treatment with PAH-specific drugs initially and then repair by cardiac defect closure has thus been attempted in patients with PAH associated with a cardiac defect. Our experience of three cases of PAH associated with VSD revealed three important points: (i) all three patients showed a response to vasoactive testing with oxygen breathing (decreased PVRi and Rp/Rs without reducing the decreased mPAP because of increased Qp/Qs); (ii) reduced PVRi 12 months after starting treatment with a combination of PAHspecific drugs; (iii) VSD closure was associated with further reduction in mPAP, although PAH-specific drugs were still required.
A treat-and-repair strategy has three merits for patients with PAH associated with a cardiac defect. First, closing the defect can prevent the progression of Eisenmenger syndrome. Although the short-term outcome in these patients is good (5-year survival 88%), 8 their survival rate reportedly declined annually after age 40 years. 8 Second,
further reduction in mPAP is obtained by shunt closure because the high flow due to S/P shunting is diminished. Third, PAH-specific drugs are easy to use after shunt closure. Pulmonary arterial hypertensionspecific drugs increase left-to-right shunting and can promote A treat-and-repair strategy is thought to be more difficult in patients with PAH associated with VSD than in those with PAH associated with an atrial septal defect which is a pretricuspid valve cardiac defect associated with volume overload in the right ventricle. In contrast, VSD is a post-tricuspid valve cardiac defect associated with both volume and pressure overload. Therefore, PAH-specific drugs in patients with VSD could easily cause right heart failure. Hence, care must be taken when using PAH-specific drugs in these patients.
The indication for defect closure is important for a successful treat-and-repair strategy. Defect closure in patients with high PVR could cause pulmonary hypertension crisis and death because shunting partially acts as a safety valve in PAH patients with CHD. 9 It was reported that defect closure in patients with high PVR associated that it is possible to close the cardiac defect. In our case series, all three patients showed a response to vasoactive testing with oxygen breathing. These criteria were fully met in Patients 2 and 3 and were almost met in patient 1. None of our three patients had post-operative complications. Hu et al. 12 reported results of a treat-and-repair strategy for 39 adult patients with PAH associated with VSD and high PVR. Six patients (15%) experienced pulmonary hypertension crises, and two patients (5%) died post-operatively. These patients did not meet the aforementioned criteria preoperatively. Sufficient reduction of the PVR or Rp/Rs by PAH-specific drugs could contribute to successful defect closure. We performed vasoreactivity testing with 100% oxygen breathing to predict operability. This effectiveness of this method, however, is controversial. The use of 100% oxygen may decrease the accuracy of flow calculations by the Fick method because a small arteriovenous oxygen difference magnifies any saturation error, which would cause lower resistance. Nitric oxide is also used for vasoreactivity testing and perhaps should be considered for predicting operability.
A fenestrated VSD patch was used in Patient 1. A fenestrated VSD patch converts a large VSD into a small VSD. This fenestration allows for a right-to-left shunt when the PAP remains high post-operatively, which could prevent pulmonary hypertensive crises, 17 although a right-to-left shunt through a fenestrated VSD patch might lead to systemic desaturation and prolonged intubation. The remaining shunting is associated with infective endocarditis and systemic embolism. 18 A pop-off valve in the VSD patch should be used in selected cases.
Conclusion
We successfully adopted a treat-and-repair strategy in adult patients with severe PAH associated with VSD. Our case series suggests that this strategy is a promising approach for adult patients with severe PAH associated with VSD.
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